Interclean Shanghai

Human Papillomavirus In Women To Be Gauged By Korean Study

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

EU Begins Revision of Medical Device...

The European Commission has gone on to initiate a...

FDA Seeks Opinion on AI-Enabled Medical...

The U.S. Food and Drug Administration (US FDA) is...

FDA Approves Zenix Monitor-Defibrillator from ZOLL

ZOLL®, which happens to be an Asahi Kasei company...

MHRA in the UK Accelerates AI...

The Medicines and Healthcare Products Regulatory Agency (MHRA) from...

The International Vaccination Institute, South Korea, has gone on to announce the beginning of multi-country research in order to better understand the challenge of Human papillomavirus in girls and women stationed across low- and middle-income countries.

This study will inform intervention implementation as well as the prioritization of research and development efforts that have the biggest potential public health impact.

The target of this worldwide HPV burden study is going to be girls and women between the age brackets of 9 and 50 across three South Asian countries as well as five sub-Saharan nations that, as of now, either have no or limited data when it comes to HPV burden, have not introduced the HPV vaccines across their national immunization programs, or have had a mixed success ratio with the uptake.

This research also includes qualitative sub studies in order to further understand how dynamics pertaining to gender create barriers to HPV prevention, treatment services, as well as screening, thereby further influencing the HPV burden amongst girls and women.

The International Vaccination Institute is also conducting a study, which happens to be in collaboration with the Ministry of Public Health of Thailand, so as to demonstrate the impact of HPV’s single dosage, therefore making the vaccines more available than the currently dominant two- or three-dose schedules.

Latest stories

Related stories

EU Begins Revision of Medical Device Regulatory Framework

The European Commission has gone on to initiate a...

FDA Seeks Opinion on AI-Enabled Medical Devices Regulation

The U.S. Food and Drug Administration (US FDA) is...

FDA Approves Zenix Monitor-Defibrillator from ZOLL

ZOLL®, which happens to be an Asahi Kasei company...

MHRA in the UK Accelerates AI Rollout in the NHS

The Medicines and Healthcare Products Regulatory Agency (MHRA) from...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »